Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy

NCT01247207 is registered in ClinicalTrials.gov with PTC Therapeutics as lead sponsor.

NCT NCT01247207
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01247207 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy
Lead sponsor
PTC Therapeutics
Phase
Phase 3
Overall status
Terminated
Start date
November 22, 2010
Completion date
February 10, 2026
Enrollment
265 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

duchenne muscular dystrophy